Clinical Trial

Number of Previous Cesarean Sections on the Results of Angiogenic Factors.

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 26, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced. Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit. Although the usefulness of angiogenic factors in these scenarios is known, little is known about the effects that other conditions might have on their serum levels, mainly those that have an effect on trophoblastic invasion, the process that initiates implantation of the pregnancy in the endometrium. The purpose of the present study is to assess the effect that a history of uterine surgery, such as caesarean section, might have on angiogenic factor scores in subjects with no history of a hypertensive disorder of pregnancy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-04; most recent amendment 2025-08-23.
Trial Details
NCT Number NCT06166303
Lead Sponsor Saint Thomas Hospital, Panama
Conditions Cesarean Section
Enrollment 540 participants
Start Date 2025-10-01
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-26